Literature DB >> 7986965

Alosetron does not affect the visceral perception of gastric distension in healthy subjects.

F Zerbib1, S Bruley des Varannes, R C Oriola, J McDonald, J P Isal, J P Galmiche.   

Abstract

BACKGROUND: The effect of alosetron, a new specific 5-HT3 receptor antagonist, on the visceral perception in response to gastric distension was assessed in 12 healthy male subjects in a randomized, double-blind, placebo controlled crossover trial.
METHODS: Each subject was given orally either alosetron 1 mg b.d. or placebo b.d. for 6 days (wash-out period 7-28 days). At the end of each dosing period, both isobarometric and isovolumetric gastric distensions were performed using an electronic barostat.
RESULTS: Alosetron did not modify the gastric wall compliance (pressure-volume relationship). Alosetron had an effect similar to placebo on the visceral perception scores in both isobarometric and isovolumetric distensions. The mean (+/- SEM) thresholds for abdominal discomfort were, respectively, 16.8 +/- 0.7 mmHg and 825 +/- 61 mL with alosetron, 16.7 +/- 0.6 mmHg and 883 +/- 45 mL with Placebo (P = NS).
CONCLUSIONS: 5-HT3 receptors do not appear to be involved in the visceral perception of gastric distension in healthy subjects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7986965     DOI: 10.1111/j.1365-2036.1994.tb00307.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  14 in total

1.  SPECT imaging of the stomach: comparison with barostat, and effects of sex, age, body mass index, and fundoplication. Single photon emission computed tomography.

Authors:  E P Bouras; S Delgado-Aros; M Camilleri; E J Castillo; D D Burton; G M Thomforde; H J Chial
Journal:  Gut       Date:  2002-12       Impact factor: 23.059

Review 2.  Pharmacology of serotonin: what a clinician should know.

Authors:  F De Ponti
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

Review 3.  New therapies for functional bowel diseases.

Authors:  B Coulie; M Camilleri
Journal:  Curr Gastroenterol Rep       Date:  2000-10

Review 4.  Alosetron.

Authors:  J A Balfour; K L Goa; C M Perry
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

Review 5.  New developments in the treatment of functional dyspepsia.

Authors:  Vincenzo Stanghellini; Fabrizio De Ponti; Roberto De Giorgio; Giovanni Barbara; Cesare Tosetti; Roberto Corinaldesi
Journal:  Drugs       Date:  2003       Impact factor: 9.546

6.  Reflux related symptoms in patients with normal oesophageal exposure to acid.

Authors:  G Shi; S Bruley des Varannes; C Scarpignato; M Le Rhun; J P Galmiche
Journal:  Gut       Date:  1995-10       Impact factor: 23.059

Review 7.  Causes and treatment of functional dyspepsia.

Authors:  J Tack; R Bisschops; B DeMarchi
Journal:  Curr Gastroenterol Rep       Date:  2001-12

Review 8.  Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.

Authors:  F De Ponti; M Tonini
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 9.  Serotonergic modulation of visceral sensation: upper gastrointestinal tract.

Authors:  J Tack; G Sarnelli
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

Review 10.  Functional GI disorders: from animal models to drug development.

Authors:  E A Mayer; S Bradesi; L Chang; B M R Spiegel; J A Bueller; B D Naliboff
Journal:  Gut       Date:  2007-10-26       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.